Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Jan-Dec:24:15347354241313344.
doi: 10.1177/15347354241313344. Epub 2025 Apr 29.

Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies

Affiliations
Meta-Analysis

Efficacy of Astragalus Membranaceus (Huang Qi) for Cancer-Related Fatigue: A Systematic Review and Meta-Analysis of Randomized Controlled Studies

Xia Sheng et al. Integr Cancer Ther. 2025 Jan-Dec.

Abstract

Background: Cancer-related fatigue is the most common complication in patients. Astragalus membranaceus is widely used in many countries to treat cancer, but its efficacy and safety is uncertain. Objectives: This study aimed to summarize the evidence on Astragalus membranaceus on cancer-related fatigue and quality of life in patients with cancer. Methods: Nine electronic databases were explored for the clinical randomized controlled trial of intervention with Astragalus membranaceus alone for cancer-related fatigue and quality of life in cancer patients from inception to July 1, 2022. The risk of bias assessment tool was adopted by Cochrane Handbook 6.1.0. The effect size was estimated using relative risk and mean difference with a corresponding 95% confidence interval. Review Manager 5.4 was used for meta-analysis. The evidence level was assessed using Grading of Recommendation, Assessment, Development and Evaluation (GRADE). Results: Eight studies were included. The results of the meta-analysis showed that the addition of Astragalus membranaceus to the control group was effective in reducing cancer-related fatigue (SMD = -1.63, 95% CI [-1.90, -1.36], P < .00001) and (RR = 1.55, 95% CI [1.19, 2.02], P = 0.001) in patients with cancer and improving quality of life (SMD = 0.86, 95% CI [0.17, 1.55], P = 0.01) and (RR = 1.57, 95% CI [1.10, 2.23], P = 0.01). Conclusion: The current evidence is supportive of the efficacy of Astragalus membranaceus in patients with cancer-related fatigue and their quality of life, but due to the small and low quality of the included literature and the lack of uniformity in terms of cancer type as well as treatment modalities, there is currently insufficient evidence to provide strong support for the clinical use of Astragalus membranaceus in the treatment of cancer-related fatigue. More high-quality evidence is needed in the future to further validate the use of Astragalus membranaceus in the treatment of clinical cancer-related fatigue. Registration: A review protocol was developed and registered in the International Prospective Register of Systematic Reviews (PROSPERO). Registration number: CRD42023442277. Registered 20 July 2023.

Keywords: CRF; Huang Qi; QoL; astragalus membranaceus; cancer-related fatigue; dietary supplements; meta-analysis; quality of life; systematic review.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram of study selection.
Figure 2.
Figure 2.
Risk of bias graph of the included studies.
Figure 3.
Figure 3.
Meta analysis of continuous variables of the influence of A. membranaceus on CRF.
Figure 4.
Figure 4.
Meta analysis of dichotomous variables of the influence of A. membranaceus CRF.
Figure 5.
Figure 5.
Meta-analysis of continuous variables of the influence of A. membranaceus on patients QoL.
Figure 6.
Figure 6.
Meta-analysis of dichotomous variables of the influence of A. membranaceus on patients’ QoL.

Similar articles

Cited by

References

    1. Sung H, Ferlay J, Siegel RL, et al.. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2021;71:209-249. - PubMed
    1. Al Maqbali M. Cancer-related fatigue: an overview. Br J Nurs. 2021;30:S36–S43. doi: 10.12968/bjon.2021.30.4.S36 - DOI - PubMed
    1. NCCN. NCCN Guidelines Version 2.2023. Cancer-Related Fatigue [EB/OL]. NCCN. https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf (2023, accessed 30 January 2023).
    1. Ma Y, He B, Jiang M, et al.. Prevalence and risk factors of cancer-related fatigue: a systematic review and meta-analysis. Int J Nurs Stud. 2020;111:103707. doi: 10.1016/j.ijnurstu.2020.103707 - DOI - PubMed
    1. Yang S, Chu S, Gao Y, et al.. A Narrative Review of Cancer-Related Fatigue (CRF) and Its Possible Pathogenesis. Cells. 2019;8:738. doi: 10.3390/cells8070738 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources